期刊文献+

香豆雌酚对成骨细胞分化过程中骨指标表达的影响(英文) 被引量:2

Effects of coumestrol on expression of bone markers during primary osteoblastic cells differentiation
下载PDF
导出
摘要 目的观察植物雌激素香豆雌酚对成骨细胞增殖分化的作用并探讨其作用机制。方法从小鼠颅盖骨获得成骨细胞并用0,10-9~10-5M香豆雌酚孵育48 h,以17β雌二醇为阳性对照,用酶消化法测定碱性磷酸酶及Ⅰ型胶原含量,放免法测定骨钙素含量,RT-PCR法测定OPG及RANKL mRNA表达情况,Western Blot测定OPG蛋白含量。结果干预48 h,不同浓度香豆雌酚呈剂量依赖性增加碱性磷酸酶及Ⅰ型胶原含量,10-6M时达到最大效应(P〈0.05),但10-5M效应有所降低,香豆雌酚轻度增加成骨细胞骨钙素含量,各组间无统计学差异。香豆雌酚呈剂量依赖性增加OPG基因及蛋白的表达(P〈0.05),轻度降低RANKL基因的表达。结论香豆雌酚能增加成骨细胞增殖及分化,可能其部分通过OPG/RANKL发挥作用。 Objective To observe the effect of phytoestrogen coumestrol on the function of osteoblast including ALP and osteocalein type I collagen, OPG and RANKL. Methods Osteoblasts obtained from fetal mouse calvaria and were incubated with coumestrol (0, 10^-9-10^-5 M) or 17β-Estradiol (10^-8 M) for 48 hours. Alkaline phosphatase (ALP) activity and type I collagen contents was measured by enzyme digestion. Osteocalein production was measured by radioimmunity. OPG and RANKL mRNA level were detected by RT-PCR and OPG protein was determined by Western Blot. Results Treated with coumestrol for 48 hours, ALP activity and type I collagen contents was dose-dependently increased by all kinds concentration of coumestrol and reached peak at 10^-6 M ( P 〈 0.05) and then decreased slightly when cotreated with 10^-5 M coumestrol. Coumestrol increased osteocalcin expression slightly, but there were no significant differences among groups. Coumestrol increased OPG mRNA expression and protein production in dose-dependently manner (P 〈 0.05) and slightly decreased RANKL mRNA expression. Conclusions Coumestrol has an enhancing effect on the proliferation and differentiation of osteoblasts, at least in part, by stimulating OPG/RANKL expression in osteoblasts.
出处 《中国骨质疏松杂志》 CAS CSCD 2009年第7期490-495,共6页 Chinese Journal of Osteoporosis
关键词 香豆雌酚 成骨细胞 OPG 骨质疏松 Coumestrol Osteoblasts Osteoprotegerin Osteoporosis
  • 相关文献

参考文献21

  • 1Ecarot B,Glorieux FH,Michel R,et al.Osteoblast isolated from mouse calvaria initiate matrix mineralization in culture.J Cell Biol,1983,96:639-643.
  • 2Canalis E,McCarthy TL,Centrella M.Factors that regulate bone formation.In:Mundy GR,Martin TJ (eds) Physiology and pharmacology of bone.Springer-Verlag,Berlin,1993,249-266.
  • 3Eastell R.Treatment of postmenopausal osteoporosis.N Engl J Med,1998,338(11):736-746.
  • 4Spelsberg TC,Subramaniam M,Riggs BL,et al.The actions and interactions of sex steroid and growth factors/cytokines on the skeleton.Mol Endocrinol,1999,13(6):819-829.
  • 5Fitzpatrick LA.Selective estrogen receptor modulators and phytoestrogens:New therapies for the postmenopausal women.Maygo Clin Proc,1999,74(6):601-607.
  • 6Adlercreutz H.Phyto-oestrogens and cancer.Lancet Oncol,2002,3(6):364-373.
  • 7Fanti P,Monier-Faugere MC,Geng Z,et al.The phytoestrogen genistein reduces bone loss in short-term ovariectomized rats.Osteoporosis Int,1998,8(3):274-281.
  • 8Yasuda H,Shima N,Nakagawa N,et al.Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG):A mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.Endocrinology,1998,139(3):1329-1337.
  • 9Teitelbaum SL.Bone resorption by osteoclasts.Science,2000,289(5484):1504-1508.
  • 10Jilka RL,Hangoc G,Girasole G,et al.Increased osteoclast development after estrogen loss:mediation by interleukin-6.Science,1992,257(5066):88-91.

同被引文献24

  • 1Tosteson AN, Do TP, Wade SW. Persistence and switching patterns among women with varied osteoporosis medication histories: 12-month results from POSSIBLE US. Osteoporos Int, 2010,10 : 1769-1780.
  • 2Meunier PJ, Roux C, Ortolani S. Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporos Int,2009,10 : 1663-1673.
  • 3Anselme K. Biomaterials and interface with bone. Osteoporos Int, 2011,6 : 2037 -2042.
  • 4Gorai I,Hori H. Effects of SERMs on bone health. Combination therapy with raloxifene. Clin Calcium,2010,3:408-412.
  • 5Erdogan MO, Yildiz H, Arran S. Association of estrogen receptor alpha and collagen type I alpha 1 gene polymorphisms with bone mineral density in postmenopausal women. Osteoporos Int, 2011,4 : 1219-25.
  • 6Schousboe JT, Bauer DC, Nyman JA. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporos Int ,2007,2:201-210.
  • 7McKiernan FE, Berg RL, Linneman JG. The utility of BMD Z- score diagnostic thresholds for secondary causes of osteoporosis. Osteoporos Int, 2011,4 : 1069-1077.
  • 8Brouwers JE, Ruchelsman M, Rietbergen B. Determination of rat vertebral bone compressive fatigue properties in untreated intact rats and zoledronic-acid-treated, ovariectomized rats. Osteoporos Int, 2009,8 : 1377-1384.
  • 9吴小涛,陈晓钢,许勇,韦继南,蒋赞利,王运涛.香豆雌酚对去卵巢大鼠成骨细胞MT1-MMP和TIMP-1基因表达的影响[J].中国骨质疏松杂志,2007,13(11):764-768. 被引量:3
  • 10PARAZZINI F,Progretto Menopausa Italia Study Group. Menopa- usal status,hormone replacement therapy use and risk of self re- ported physician-diagnosed osteoarthrit is in women attending menopause clinics in Italy[J]. Maturitas,2003,46(3):207-212.

引证文献2

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部